{"id":"adalimumab-ada","safety":{"commonSideEffects":[{"rate":"12-26%","effect":"Injection site reactions"},{"rate":"7-17%","effect":"Upper respiratory tract infections"},{"rate":"12%","effect":"Headache"},{"rate":"0.1-0.3%","effect":"Tuberculosis reactivation"},{"rate":"1-3%","effect":"Opportunistic infections"},{"rate":"increased relative risk","effect":"Malignancy risk"}]},"_chembl":{"chemblId":"CHEMBL1201580","moleculeType":"Antibody"},"_dailymed":{"setId":"9c44bd5b-4464-40a4-8933-8680950f00f2","title":"AMJEVITA (ADALIMUMAB-ATTO) INJECTION [AMGEN, INC]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By blocking TNF-α, adalimumab reduces inflammatory signaling and immune activation in conditions driven by excessive TNF-α production. This leads to decreased inflammation, reduced immune cell infiltration, and suppression of downstream inflammatory mediators. It is used across multiple autoimmune and inflammatory conditions where TNF-α plays a central pathogenic role.","oneSentence":"Adalimumab is a monoclonal antibody that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), a key inflammatory cytokine.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:42:02.385Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Crohn's disease"},{"name":"Ulcerative colitis"},{"name":"Ankylosing spondylitis"},{"name":"Psoriatic arthritis"},{"name":"Psoriasis"},{"name":"Juvenile idiopathic arthritis"},{"name":"Polyarticular juvenile idiopathic arthritis"}]},"trialDetails":[{"nctId":"NCT06390436","phase":"PHASE4","title":"Therapeutic Drug Monitoring-baSed adalimuMab De-escalatiOn in nOn-infecTious cHronic Uveitis","status":"NOT_YET_RECRUITING","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2025-06","conditions":"Uveitis, Chronic Disease","enrollment":320},{"nctId":"NCT06640517","phase":"PHASE3","title":"Study of the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of Netakimab in Children With Moderate to Severe Plaque Psoriasis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Biocad","startDate":"2024-08-08","conditions":"Plaque Psoriasis","enrollment":140},{"nctId":"NCT06310837","phase":"NA","title":"Effect of Immunosuppressants With Adalimumab Biosimilars vs Corticosteroids on Noninfectious Uveitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Zhongshan Ophthalmic Center, Sun Yat-sen University","startDate":"2024-03-27","conditions":"Uveitis","enrollment":128},{"nctId":"NCT03828019","phase":"PHASE3","title":"Adalimumab vs. Conventional Immunosuppression for Uveitis Trial","status":"COMPLETED","sponsor":"JHSPH Center for Clinical Trials","startDate":"2019-09-16","conditions":"Uveitis","enrollment":227},{"nctId":"NCT03505008","phase":"PHASE4","title":"Evaluation of the Optimal MTX Dose as an Add-on Therapy to Adalimumab for RA Patients in Japan, South Korea and Taiwan","status":"COMPLETED","sponsor":"Keio University","startDate":"2018-04-18","conditions":"Rheumatoid Arthritis","enrollment":300},{"nctId":"NCT06849908","phase":"PHASE2","title":"Baricitinib in the Treatment of Intestinal Behçet's Syndrome","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2024-11-08","conditions":"Behcet Syndrome, Intestinal Type","enrollment":56},{"nctId":"NCT06849739","phase":"","title":"Study on the Correlation and Consistency of Measuring Biologic Drug Plasma Concentrations Based on Different Detection Methods","status":"NOT_YET_RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2025-03-02","conditions":"Inflammatory Bowel Diseases","enrollment":60},{"nctId":"NCT03445845","phase":"PHASE4","title":"Rotation or Change of Biotherapy After TNF Blocker Treatment Failure for Axial Spondyloarthritis","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2018-12-14","conditions":"Axial Spondyloarthritis","enrollment":300},{"nctId":"NCT06498089","phase":"PHASE4","title":"A Randomized, Controlled, Open-label, Multicenter Clinical Trial Comparing the Efficacy and Safety of a Precision Treatment Regimen Based on Clinical-molecular Phenotypes with a Conventional Treatment Regimen in the Treatment of Patients with Active Takayasu's Arteritis","status":"RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2024-06-28","conditions":"Takayasu Arteritis","enrollment":124},{"nctId":"NCT04028713","phase":"PHASE4","title":"Dose Tapering Study of Adalimumab in Psoriasis","status":"TERMINATED","sponsor":"University Hospital, Ghent","startDate":"2021-02-16","conditions":"Psoriasis Vulgaris","enrollment":19},{"nctId":"NCT05460390","phase":"NA","title":"Proactive Therapeutic Drug Monitoring Based Adalimumab Therapy Optimization in Patients With Rheumatoid Arthritis","status":"TERMINATED","sponsor":"Boston Medical Center","startDate":"2022-10-26","conditions":"Rheumatoid Arthritis","enrollment":5},{"nctId":"NCT05291039","phase":"NA","title":"Infliximab and Adalimumab in Inflammatory Bowel Disease Patients.","status":"COMPLETED","sponsor":"Rehab Werida","startDate":"2022-01-01","conditions":"Inflammatory Bowel Diseases","enrollment":56},{"nctId":"NCT05527444","phase":"PHASE4","title":"The Clinical Efficacy and the Changes of Immune Cells Subsets With Bioagents in Ankylosing Spondylitis Patients","status":"UNKNOWN","sponsor":"Qilu Hospital of Shandong University","startDate":"2022-03-15","conditions":"Ankylosing Spondylitis","enrollment":100},{"nctId":"NCT04360785","phase":"NA","title":"Effect of Two Methotrexate in Sync With the First Adalimumab to Prevent the Immunisation Anti Ada in Spondyloarthritis","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2020-11-11","conditions":"Spondyloarthritis","enrollment":124},{"nctId":"NCT05683054","phase":"PHASE4","title":"A Non-inferiority Study on Dose Reduction of Adalimumab in Psoriasis Patients Who Are Overtreated","status":"COMPLETED","sponsor":"University Hospital, Ghent","startDate":"2020-08-11","conditions":"Psoriasis","enrollment":19},{"nctId":"NCT01971970","phase":"","title":"Biomarkers of Anti-TNF Treatment in Inflammatory Bowel Disease (IBD)","status":"COMPLETED","sponsor":"Erasmus Medical Center","startDate":"2013-10","conditions":"Inflammatory Bowel Diseases","enrollment":45},{"nctId":"NCT04042792","phase":"","title":"Characterization of Adalimumab Concentrations in Pediatric Patients With Inflammatory Rheumatic Disease With and Without Methotrexate","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2019-09-26","conditions":"Rheumatic Diseases","enrollment":28},{"nctId":"NCT05015335","phase":"PHASE4","title":"The Efficacy and Safety of Adalimumab in Non-infectious Anterior Pediatric Uveitis With Peripheral Vascular Leakage","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2021-08-19","conditions":"Uveitis, Anterior, Adalimumab","enrollment":50},{"nctId":"NCT02471118","phase":"PHASE2","title":"Osteoarthritis of the Knee, Inflammation, and the Effect of Adalimumab (OKINADA)","status":"COMPLETED","sponsor":"CARE ARTHRITIS LTD.","startDate":"2015-03","conditions":"Osteoarthritis, Knee","enrollment":62},{"nctId":"NCT02256462","phase":"PHASE4","title":"Pediatric Crohn's Disease AdalImumab Level-based Optimization Treatment (PAILOT) Trial","status":"COMPLETED","sponsor":"Schneider Children's Medical Center, Israel","startDate":"2015-05-01","conditions":"Crohn's Disease","enrollment":82},{"nctId":"NCT04131322","phase":"PHASE4","title":"Loss of Response of Adalimumab Biosimilar vs Adalimumab Original, in Inflammatory Bowel Disease.","status":"TERMINATED","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","startDate":"2019-10-10","conditions":"Crohn Disease, Ulcerative Colitis","enrollment":24},{"nctId":"NCT02814175","phase":"PHASE4","title":"A Study of Subjects With Psoriatic Arthritis to Investigate the Effectiveness of Adalimumab Introduction Compared With Methotrexate Dose Escalation (CONTROL)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-08-05","conditions":"Psoriatic Arthritis","enrollment":246},{"nctId":"NCT03217734","phase":"PHASE2, PHASE3","title":"MAP Study: Methotrexate and Adalimumab in Psoriasis","status":"COMPLETED","sponsor":"Jeffrey J Crowley MD","startDate":"2017-04-10","conditions":"Psoriasis","enrollment":56},{"nctId":"NCT01500278","phase":"PHASE4","title":"Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate","status":"COMPLETED","sponsor":"UCB Pharma SA","startDate":"2011-12","conditions":"Rheumatoid Arthritis","enrollment":915},{"nctId":"NCT03580876","phase":"PHASE4","title":"Addition of Azathioprine in IBD Patients With Immunogenic Failure","status":"UNKNOWN","sponsor":"Védrines, Philippe, M.D.","startDate":"2018-07-23","conditions":"Clinical Failure After Switch","enrollment":90},{"nctId":"NCT01383421","phase":"","title":"Observational Study to Explore the Effectiveness of Adalimumab Treatment in Conjunction With Utilization of a Patient Support Program (PSP)","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2011-09","conditions":"Rheumatoid Arthritis","enrollment":1036},{"nctId":"NCT02016482","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chronic Plaque Psoriasis and Nail Psoriasis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-01","conditions":"Nail Psoriasis, Plaque Psoriasis","enrollment":217},{"nctId":"NCT02116504","phase":"NA","title":"Anti-Biopharmaceutical Immunization: Prediction and Analysis of Clinical Relevance to Minimize the Risk of Immunization in Rheumatoid Arthritis Patients or Juvenile Idiopathic Arthritis Patients","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2014-04","conditions":"Rheumatoid Arthritis, Juvenile Idiopathic Arthritis","enrollment":156},{"nctId":"NCT02878161","phase":"PHASE4","title":"Predictability Studies on the Efficacy of TNF-α Inhibitors in Chinese RA From \"Real World\"","status":"UNKNOWN","sponsor":"Fen Li","startDate":"2016-01","conditions":"Rheumatoid Arthritis","enrollment":240},{"nctId":"NCT01960426","phase":"PHASE4","title":"Evaluation of Health Costs and Resource Utilization","status":"TERMINATED","sponsor":"University of Western Ontario, Canada","startDate":"2014-04","conditions":"Ulcerative Colitis, Crohn's Disease","enrollment":51},{"nctId":"NCT01981473","phase":"","title":"Drug Concentration, Immunogenicity, and Efficacy Study in Patients With Rheumatoid Arthritis Currently Treated With Etanercept, Adalimumab, or Infliximab","status":"COMPLETED","sponsor":"Pfizer","startDate":"2014-01","conditions":"Rheumatoid Arthritis","enrollment":605},{"nctId":"NCT01783015","phase":"PHASE4","title":"Study of Etanercept in Subjects With Rheumatoid Arthritis Who Have Had an Inadequate Response to Adalimumab or Infliximab Plus Methotrexate","status":"TERMINATED","sponsor":"Pfizer","startDate":"2013-09","conditions":"Rheumatoid Arthritis","enrollment":16},{"nctId":"NCT00724672","phase":"","title":"A Study of Immune Cells in Patients With Rheumatoid Arthritis During Different Types of Anti-TNF Alpha Treatments (Study P05521)","status":"WITHDRAWN","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-09","conditions":"Rheumatoid Arthritis","enrollment":""},{"nctId":"NCT01185301","phase":"PHASE3","title":"Study to Determine the Effects of Different Doses of Methotrexate (MTX) When Taken With Adalimumab in Subjects With Early Rheumatoid Arthritis (RA)","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2010-10","conditions":"Early Rheumatoid Arthritis","enrollment":395},{"nctId":"NCT00420927","phase":"PHASE4","title":"Study of the Optimal Protocol for Methotrexate and Adalimumab Combination Therapy in Early Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Abbott","startDate":"2006-12","conditions":"Rheumatoid Arthritis","enrollment":1032},{"nctId":"NCT01270035","phase":"PHASE4","title":"Efficacy and Safety of Adalimumab 80 mg Every Other Week With Methotrexate","status":"UNKNOWN","sponsor":"Keio University","startDate":"2011-01","conditions":"Rheumatoid Arthritis","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Adalimumab, Humira","Humira","ADA"],"phase":"marketed","status":"active","brandName":"Adalimumab (ADA)","genericName":"Adalimumab (ADA)","companyName":"JHSPH Center for Clinical Trials","companyId":"jhsph-center-for-clinical-trials","modality":"Biologic","firstApprovalDate":"","aiSummary":"Adalimumab is a monoclonal antibody that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), a key inflammatory cytokine. Used for Rheumatoid arthritis, Crohn's disease, Ulcerative colitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}